Paris, France – 12 October 2009 – DBV Technologies, a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, announced today that it has signed a distribution agreement with BIOPROJET pharma for DBV’s Cow’s Milk protein allergy diagnostic, Diallertest® Milk. Under the terms of the agreement, BIOPROJET Pharma will promote and distribute Diallertest® Milk in France.
BIOPROJET pharma, a French paediatric focused pharmaceutical company, markets a number of products in France including Tiorfan® ( a leading anti-diarrheal drug) Fanomer® (a nasal spray for children) and Fanolyte® (an oral rehydration solution). Since 2002, BIOPROJET Pharma has extended its distribution networks to include major European and overseas markets.
“We are extremely pleased to have signed this distribution deal with BIOPROJET Pharma,” said DBV Technologies Chairman and CEO Jean François Biry. “The agreement will enable wider access to a diagnostic for a condition that is very difficult to diagnose which is also the cause of significant pain and distress for infants.”
“Diallertest® Milk is a non-invasive, easy to use and pain free approach for the diagnosis of cow’s milk protein allergy. “It fits well with our existing product range and we look forward to working with DBV to make Diallertest® Milk more widely available throughout Europe”, commented BIOPROJET Pharma CEO Dr. Jeanne-Marie Lecomte.
DBV Technologies is currently working on the further development of its Diallertest® product range for the diagnosis of wheat, soya and dustmite allergies in children.
About DBV Technologies - www.dbv-technologies.com
DBV Technologies is a speciality pharma company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergy diagnosis and treatment. The Company is lead by CEO Jean-François Biry and was born out of the experience of Professor christophe Dupont, a paediatric GI from Assistance Publique-Hôpitaiux de Paris and Universiy Paris Descartes Doctor Pierre-Henri Benhamou, a paediatrician specialising in gastro-enterology, allergosis and nutrition, and Bertrand Dupont, a qualified engineer from the Arts et Métiers Institute. DBV Technologies’ lead product, Diallertest® Milk, is on sale in France and other countries for the diagnosis of cow’s milk protein allergy.
DBV closed a €6million (EUR) Series B investment in January 2009 with new investor ALK-Abello, a leading worldwide immunotherapy company, and returning investor Sofinnova Partners.
DBV Technologies was founded in 2002 and is based in the Pépinière Paris Santé Cochin, in Paris’ 14th arrondissement.
About VIASKIN®
DBV Technologies’ globally patented VIASKIN® technology is a unique delivery system which retains active compounds on a carrier using electrostatic forces only. The delivery platform allows active compounds to be presented to the epidermis of the skin without breaking the blood-skin barrier. In not breaking the blood-skin barrier, DBV Technologies’ allergen diagnosis and specific immunotherapy treatments avoid inducing systemic shock – one of the most serious concerns associated with current desensitisation therapies.
DBV Technologies’ VIASKIN® technology is in development for the treatment of allergies through Epicutaneous Specific Immunotherapy (EPIT) and for the administration of vaccines. The company is currently seeking partnerships in these areas DBV Technologies’ lead product, Diallertest® Milk, utilises VIASKIN® technology and is on sale in France and other countries for the diagnosis of cow’s milk protein allergy.
To view a video of VIASKIN presenting active compounds to the skin without breaking the blood-skin barrier, please click on the link http://www.dbv-technologies.com/viaskin-technology/about.htm
About Diallertest® Milk
DBV Technologies’ lead product, Diallertest® Milk, is on sale in France and other countries for the diagnosis of cow’s milk protein allergy. Diallertest® Milk represents a revolution for paediatrics and was awarded an International prize for Technological Innovation by the Altran foundation in 2003.
